PO.PS01.01 · 人群科学
代谢组学与肝癌风险:前瞻性研究的系统评价
Metabolomics and liver cancer risk: A systematic review of prospective studies
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言 新兴的代谢组学研究已识别出与肝癌相关的循环代谢物,但不同人群中的证据仍不一致。为弥补这些空白,我们开展了迄今为止最全面的前瞻性代谢组学研究系统评价,整合不同人群的结果以识别肝癌的代谢特征。
方法 我们遵循系统评价和荟萃分析首选报告条目(PRISMA)指南报告我们的发现。我们系统检索了截至2025年1月的PubMed,以查找检查诊断前循环代谢组学特征与肝癌的前瞻性队列或巢式病例对照研究。两名评审员独立筛选、提取和评估研究。由于研究设计和结局报告的异质性,采用描述性方法综合结果。总结了代谢物关联的方向和效应量。对与肝癌显著相关的代谢物进行了富集分析。
结果 纳入了24项前瞻性研究,其中8项巢式病例对照或队列研究包含1,626例肝癌病例,提供了每标准差(SD)增加的风险估计值。7项研究使用液相色谱-质谱法,1项使用核磁共振。在这些研究中,共评估了98种独特的代谢物,并观察到肝癌发生前一致的代谢改变。升高的芳香族氨基酸(酪氨酸、苯丙氨酸)、谷氨酸、精氨酸和结合型胆汁酸与肝癌风险呈正相关,风险比(每SD增加的RR)范围为1.49至5.82,而支链氨基酸(亮氨酸和异亮氨酸)、赖氨酸、谷氨酰胺和溶血磷脂酰胆碱显示出负相关,RR范围为0.15至0.75。饱和磷脂酰胆碱、鞘氨醇和部分氨基酸衍生物(胱硫醚、犬尿氨酸)呈正相关(RR为1.62-3.32),而雄激素硫酸盐和肌酸呈负相关(RR为0.20-0.56)。在大多数24项前瞻性研究中,方向总体一致。富集程度最高的三条通路是牛磺酸和亚牛磺酸代谢、缬氨酸/亮氨酸和异亮氨酸生物合成以及精氨酸生物合成。
结论 我们的系统评价表明,肝癌风险与芳香族氨基酸增加、胆汁酸结合和脂质重塑以及支链氨基酸和雄激素类固醇减少相关。所识别的代谢特征可为未来肝癌的风险预测、早期检测和靶向预防工作提供参考。
查看英文原文 English abstract
Introduction Emerging metabolomic studies have identified circulating metabolites associated with liver cancer, yet evidence remains inconsistent across populations. To address these gaps, we conducted the most comprehensive systematic review of prospective metabolomic studies to date, integrating results across different populations to identify metabolic signatures of liver cancer.
Methods We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to report our findings. We systematically searched PubMed through January 2025, for prospective cohort or nested case-control studies examining pre-diagnostic circulating metabolomic profiles with liver cancer. Two reviewers independently screened, extracted, and evaluated studies. Due to heterogeneity in study design and outcome reporting, findings were synthesized descriptively. Direction and effect size of metabolite associations was summarized. Enrichment analysis was conducted for those metabolites significantly associated with liver cancer.
Results Twenty-four prospective studies were included, of which eight nested case-control or cohort studies with 1,626 cases of liver cancer, providing risk estimates for per standard deviation (SD) increase. Seven studies used liquid chromatography-mass spectrometry and one used nuclear magnetic resonance. Across these studies, 98 unique metabolites were evaluated, and consistent metabolic alterations preceding liver cancer were observed. Elevated aromatic amino acids (tyrosine, phenylalanine), glutamate, arginine, and conjugated bile acids were positively associated with liver cancer risk with risk ratios (RRs for per SD increase) ranging from 1.49 to 5.82, whereas branched-chain amino acids (leucine and isoleucine), lysine, glutamine, and lysophosphatidylcholines showed inverse associations with RRs ranging from 0.15 to 0.75. Saturated phosphatidylcholine, sphingosine, and select amino acid derivatives (cystathionine, kynurenine) were positively associated (RRs, 1.62-3.32), while androgen sulfates and creatine were inversely related (RRs, 0.20-0.56). The direction was generally consistent across the majority of the 24 prospective studies. Three most enriched pathways were taurine and hypotaurine metabolism, valine/leucine and isoleucine biosynthesis, and arginine biosynthesis.
Conclusions Our systematic review indicates that liver cancer risk was associated with increased aromatic amino acids, bile acid conjugation, and lipid remodeling, and decreased branched-chain amino acids and androgenic steroids. The identified metabolic signatures may inform future efforts in risk prediction, early detection, and targeted prevention for liver cancer.
利益披露 Disclosure
L. Zhao, None..
M. Hu, None..
Y. Chen, None..
X. Zhang, None..
X. Zhang, None.